Table 1.
Characteristics of newly diagnosed celiac disease patients (n=148)
| Number (%) | |
|---|---|
|
| |
| Age (mean/median, SD) | 40.4/41.2, 14.6 |
|
| |
| Location of diagnosis | |
| CUMC | 73 (49) |
| BIDMC | 75 (51) |
|
| |
| Gender | |
| Male | 46 (31) |
| Female | 102 (69) |
|
| |
| Mode of presentation | |
| Classical | 62 (42) |
| Non-classical | 86 (58) |
|
| |
| Serologic status at time of endoscopy (TTG/DGP/EMA)* | |
| Seropositive | 136 (93) |
| Seronegative | 11 (7) |
|
| |
| Acid suppression medication status | |
| PPI and H2RA use | 3 (2) |
| PPI or H2RA use | 19 (13) |
| Any PPI use | 18 (12) |
| Any H2RA use | 7 (5) |
| No acid suppression medication use | 126 (85) |
|
| |
| Aspirin/NSAID use | |
| Both Aspirin and NSAID use | 3 (2) |
| Aspirin or NSAID use | 27 (18) |
| Any Aspirin use | 16 (11) |
| Any NSAID use | 17 (11) |
| No Aspirin or NSAID use | 118 (80) |
|
| |
| H. pylori gastritis | 4/88 (5) |
Legend: CUMC: Columbia University Medical Center; BIDMC: Beth Israel Deaconess Medical Center; H2RA: Histamine-2-receptor antagonists; PPI: Proton Pump Inhibitor; NSAID: Nonsteroidal anti-inflammatory drugs
*
Serologic status was unknown for 1 patient